Trial Profile
A Randomized Phase 2 Study in Patients With Triple-negative Androgen Receptor Positive Locally Recurrent (Unresectable) or Metastatic Breast Cancer Treated With Darolutamide or Capecitabine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Darolutamide (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms START
- 18 Nov 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Primary endpoint has not been met (clinical benefit rate) , according to Results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress